Charting Your Path to Principal Investigator: What It…
A practical roadmap through education, GCP training, site infrastructure, and sponsor selection in a tightening investigator market. · The pool of active…
Posts – August 2026
Public posts from August 2026, newest first. Each heading links to the post.
Moldova Is Eastern Europe’s Most Underestimated Clinical…
Treatment naive patient access, low operating costs and EU accession driven regulatory modernization make Moldova a serious early mover opportunity. · Moldova…
Why Your Protocol Is Already Your Biggest Operational…
A rushed or poorly designed protocol creates cascading delays that no amount of operational skill can fix. · By the time your first patient enrolls, the…
Cardiometabolic programs move into broader clinical testing
Edition 15 shows continued activity across cardiovascular, metabolic and respiratory related development programs · Cardiometabolic is one of the strongest…
RAG and Vector Search: Smarter Document Retrieval for…
How retrieval-augmented generation helps sites and sponsors find the right protocol language, eligibility criteria, and regulatory guidance faster. · Clinical…
Clinical Development Moves Into Bigger and More Complex…
The first half of August shows strong activity across cardiometabolic, immunology, oncology, neurology and advanced modality programs. · Trial Watch Edition…
Agentic AI vs AI-Assisted Tools: What's Actually Different…
The distinction matters for sites because protocol consistency directly affects amendment rates, enrollment delays, and deviation risk. · Most protocol tools…
Albania Is an Emerging Clinical Trial Opportunity in the…
Treatment naive patient access, EU accession momentum and a Tirana centered hospital ecosystem make Albania a strategic early mover market. · Albania is one…
Audit Trails for AI in Clinical Trials: New Rules You Need…
From ICH E6(R3) to the EU AI Act, regulators now expect the same traceability for AI-generated documents as your EDC system. · When FDA inspected Applied…
Oncology programs push combination strategy into late…
ADCs, bispecifics and genotype directed therapy are moving into more ambitious oncology trial designs. · Oncology contributes five high signal trials in Trial…
Cut Screen Failures: How CTMS Pre-Screening Stops…
Screen failure rates can hit 70% in some trials. Structured pre-screening workflows catch disqualifying criteria before consent, saving time and money. · A…
Trial Watch 14: Advanced modalities create a new…
As CAR T and T cell redirecting therapies scale, sponsors are now testing the systems needed to manage their complications. · Advanced modalities in Trial…
ICH E6(R3) Creates New Compliance Rules for AI-Generated…
Quality by design requirements now apply to how you draft protocols, not just what's in them. · The final version of ICH E6(R3) took effect in the EU in July…
North Macedonia Is an Emerging Balkan Clinical Trial Market
EU accession momentum, Skopje based research infrastructure and treatment naive patient access make North Macedonia a useful add on market for Balkan studies…
Why Half Your Oncology Screened Patients May Fail…
Manual chart review takes an hour per patient and misses the pace of oncology. Automated screening is cutting coordinator workload by up to 85%. · A major…
Cardiometabolic programs move into large scale clinical…
Edition 14 shows continued sponsor activity across cardiovascular, liver health and metabolic programs. · Cardiometabolic is one of the strongest areas in…
Fine-Tuned Clinical LLMs vs General AI: What Actually…
Recent evidence challenges the assumption that domain-specific AI models outperform general ones for clinical research tasks. · The clinical research…
Bosnia and Herzegovina Is an Untapped Balkan Clinical…
EU accession momentum, low operating costs and anchor sites in Sarajevo and Banja Luka make Bosnia a long term regional opportunity for sponsors. · Bosnia and…
Why Your AI-Generated Trial Documents Need Real Human…
New research shows baseline AI produces factual errors in up to 43% of clinical documents, but structured human review can push accuracy above 90%. · Large…
Slovenia Is a Small EU Trial Market With Outsized Research…
A centralized healthcare system, single national ethics committee and strong investigator base make Slovenia a high quality clinical research destination. ·…
Protocol Amendments: Understanding the Nine-Month…
Why a two-paragraph protocol change can trigger a nine-month implementation cycle across your site network. · A substantial protocol amendment in a Phase III…
Croatia Is the Balkans’ Strongest Clinical Trial Market…
EU regulation, Zagreb’s hospital network and strong per capita trial density make Croatia a valuable Southeast European research market. · Croatia is a…
Why Clinical AI Infrastructure Is a Compliance Risk, Not…
New HIPAA rules and FDA guidance are forcing sponsors to rethink where their AI runs and who controls the data. · When you submit a protocol draft to an AI…
Serbia Is the Balkans’ Rising Clinical Research Powerhouse
Experienced investigators, compact site geography and recent regulatory reform make Serbia a strong non EU option for sponsors. · Serbia is becoming one of…
Why Your Next Trial May Run on a Clinical Trial Operating…
The industry is moving from stitched-together software toward unified platforms that automate protocol execution. · Clinical trial infrastructure wasn't…
Slovakia Is a Compact EU Clinical Trial Market With Strong…
EU aligned regulation, CEE cost efficiency and the Bratislava Vienna corridor make Slovakia a strategic option for regional and multi country studies. ·…
Clinical Study Reports: What Sites Should Know About the CSR
The definitive scientific account of your trial doesn't end at database lock. Here's how CSRs work and why they matter for sites. · After your Phase III trial…
CDISC Standards: What Site Staff Need to Know About…
How global data standards shape what you collect at the site level and why early adoption matters for sponsors and CROs. · Before CDISC, every sponsor…
AI-Native Clinical Operations: What the Evidence Actually…
Why leading sponsors are rebuilding trial infrastructure around AI coordination, not just adding AI tools to existing workflows. · At the 2026 SCOPE Summit…
FDA and EMA Converge on AI Expectations for Clinical…
New guidance frameworks create overlapping accountability for AI used in regulatory submissions, from trial protocols to pharmacovigilance. · Between…
Four Budget Pitfalls That Quietly Drain Clinical Trial…
Protocol amendments, slow enrollment, site payment disputes, and vague vendor contracts drive most overruns, but planning strategies can contain them. ·…
Bulgaria Is One of Europe’s Most Efficient Clinical Trial…
Fast approvals, strong retention, EU alignment and competitive costs make Bulgaria a high value destination for sponsors. · Bulgaria is one of Europe’s most…
Why Protocol Design Has Become Your Trial's Biggest…
Three out of four protocols now require substantial amendments, each costing over half a million dollars and 260 days to implement. · Protocol complexity has…